{"id":7593,"date":"2026-06-06T13:00:33","date_gmt":"2026-06-06T13:00:33","guid":{"rendered":"https:\/\/autism.fratnow.com\/blog\/?p=7593"},"modified":"2026-06-06T13:03:16","modified_gmt":"2026-06-06T13:03:16","slug":"blocking-vs-binding-folate-receptor-autoantibodies","status":"publish","type":"post","link":"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/","title":{"rendered":"Blocking vs. Binding Folate Receptor Autoantibodies"},"content":{"rendered":"<p>[vc_row][vc_column][vc_single_image image=&#8221;7594&#8243; img_size=&#8221;full&#8221;][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;Introduction&#8221;][vc_column_text single_style=&#8221;&#8221;]Folate receptor alpha (FR\u03b1) is a glycosylphosphatidylinositol (GPI)-anchored protein highly expressed on the apical surface of choroid plexus epithelial cells. This receptor is also present in the placenta, kidney, lung, among other tissues. Its primary function in the central nervous system (CNS) is to transport <strong>5-methyltetrahydrofolate<\/strong> (the active form of folate) from the blood across the blood-cerebrospinal fluid barrier into the brain.<br \/>\n[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]Autoantibodies against FR\u03b1 have been implicated in <a href=\"https:\/\/autism.fratnow.com\/blog\/cerebral-folate-deficiency-an-overview\/\">Cerebral Folate Deficiency (CFD)<\/a>, a condition characterized by low cerebrospinal fluid (CSF) folate levels despite normal serum folate. CFD, which has been in the news as of late, is associated with neurodevelopmental disorders, including <a href=\"https:\/\/autism.fratnow.com\/blog\/a-comprehensive-introduction-to-autism-spectrum-disorder\/\">autism spectrum disorder (ASD)<\/a>, epilepsy, and regression syndromes. Most interestingly, there are two distinct functional classes of these autoantibodies: blocking and binding antibodies. Despite a common target, their mechanisms, detection methods, and clinical correlations differ significantly.[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]Both blocking and binding autoantibodies are detected by the<strong> FRAT<sup>\u00ae<\/sup> test<\/strong>.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;Blocking Folate Receptor Autoantibodies (Blocking FRAs)&#8221;][vc_column_text single_style=&#8221;&#8221;]Blocking FRAs are autoantibodies that bind directly to the <strong>folate-binding site<\/strong> or a critical conformational epitope on FR\u03b1. Their binding functionally inhibits the ability of the receptor to bind its natural ligand\u20145-methyltetrahydrofolate. This is an <strong>orthosteric antagonism<\/strong> mechanism; a mechanism where a molecule (the antagonist) binds directly to the <strong>primary, active binding site<\/strong> of a receptor\u2014the same site where the natural ligand (e.g., folate) is supposed to bind. By occupying this site, the antagonist physically blocks the natural ligand from attaching, thereby preventing receptor activation or function.<br \/>\n[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]The major consequence in this instance is the Immediate and direct blockade of folate transport across the choroid plexus, leading to a functional folate deficiency in the brain even when serum folate levels are normal.<\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;Clinical Associations&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<ul>\n<li><strong>Cerebral Folate Deficiency<\/strong> (especially infantile-onset)<\/li>\n<li><strong> Autism Spectrum Disorder<\/strong> with regressive features<\/li>\n<li><strong>Rett syndrome<\/strong> (subset of patients)<\/li>\n<li><strong>Pregnancy complications <\/strong>\u2013 low maternal folate transport to fetus<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;Pathophysiological Uniqueness&#8221;][vc_column_text single_style=&#8221;&#8221;]Blocking FRAs act as <strong>pharmacological antagonists<\/strong>. They produce an acute inhibition of folate transport. Their effect is measurable in vitro via loss of ligand binding. Importantly, their effects can be overcome by supraphysiological concentrations of folinic acid (not folic acid), which uses a different transport system (reduced folate carrier, RFC) at high doses.<br \/>\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;Binding Folate Receptor Autoantibodies (Binding FRAs)&#8221;][vc_column_text single_style=&#8221;&#8221;]Binding FRAs recognize FR\u03b1 but<strong> do not<\/strong> directly block the folate-binding pocket. Instead, they bind to <strong>non-blocking epitopes<\/strong> on the receptor, typically on the extracellular domain distal to the ligand-binding site. Their pathological mechanism is indirect and <strong>immune-mediated<\/strong>.<br \/>\n[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]It seems that there is no immediate inhibition of folate binding, but instead, binding autoantibodies:<\/p>\n<ul>\n<li>Induce internalization and degradation of FR\u03b1.<\/li>\n<li>Activate complement-mediated lysis of FR\u03b1-expressing cells.<\/li>\n<li>Trigger chronic inflammation at the choroid plexus.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]Clinical associations are similar to that of blocking autoantibodies. These can include:<\/p>\n<ul>\n<li><strong>Non-regressive ASD<\/strong> (more common than blocking antibodies in some cohorts)<\/li>\n<li><strong><a href=\"https:\/\/autism.fratnow.com\/blog\/folate-folate-receptor-autoantibodies-neural-tube-defects\/\">Neural tube defects<\/a> (maternal binding FRAs)<\/strong><\/li>\n<li><strong>Recurrent pregnancy loss<\/strong><\/li>\n<li><strong>Subfertility<\/strong><\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;Pathophysiological Uniqueness&#8221;][vc_column_text single_style=&#8221;&#8221;]Binding FRAs act as<strong> immune effectors<\/strong>. They do not directly interrupt ligand binding but progressively eliminate the receptor from the cell surface. Their effect is not immediately reversible by adding excess folate\u2014if the receptor is gone, transport ceases permanently until receptor resynthesis. This creates a slower onset, but more sustained deficiency compared to blocking antibodies.<br \/>\n[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<table class=\"table-section-356325\" style=\"border-collapse: collapse; width: 100%;\">\n<tbody>\n<tr style=\"background-color: #f2f2f2;\">\n<td style=\"border: 1px solid #ccc; padding: 8px; white-space: nowrap;\"><strong>Parameter<\/strong><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Blocking FRA<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Binding FRA<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Epitope location<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Folate-binding pocket or allosteric site causing conformational occlusion<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Distal, non-blocking extracellular domains<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Direct inhibition of folate binding<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Yes<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">No<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Mechanism of pathology<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Orthosteric antagonism (functional blockade)<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Immune destruction<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Primary assay<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Competitive inhibition assay (functional)<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Direct binding ELISA (non-functional)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Main IgG subclasses<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">IgG1, IgG4<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">IgG1, IgG4<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Effect on FR\u03b1 cell surface density<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">No direct reduction<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Reduces surface density via internalization\/lysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Time to CSF folate decline<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Days (rapid onset)<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Weeks (gradual onset)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Overcome by high-dose folinic acid<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Yes \u2013 via reduced folate carrier<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Partial \u2013 requires intact FR\u03b1 or high RFC<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Associated neurophenotype<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">More regressive ASD, acute neurological decline<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">More static, non-regressive autism, autoimmune clustering<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;Clinical and Therapeutic Implications of Their Uniqueness&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<table class=\"table-section-356325\" style=\"border-collapse: collapse; width: 100%;\">\n<tbody>\n<tr style=\"background-color: #f2f2f2;\">\n<td style=\"border: 1px solid #ccc; padding: 8px; white-space: nowrap;\"><strong>Aspect<\/strong><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Blocking FRA<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Binding FRA<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>First-line therapy<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">High-dose folinic acid (bypasses blockade)<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">High-dose folinic acid + immunomodulation (IVIG, steroids)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Response to folinic acid alone<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Good to excellent<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Partial (if receptor loss significant)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Role of immunosuppression<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Rarely needed<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Often required to stop new receptor destruction<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\"><b>Prognosis<\/b><\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Better if treated early<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">More guarded if receptor depletion is advanced<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=&#8221;Conclusion&#8221;][vc_column_text single_style=&#8221;&#8221;]<strong>Blocking FRAs<\/strong> are unique because they directly and reversibly inhibit folate binding to FR\u03b1 without destroying the receptor, acting as competitive antagonists of a vitamin transport system \u2013 a rare autoimmune mechanism. Their effect can be overcome pharmacologically.<br \/>\n[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]<strong>Binding FRAs<\/strong> are unique because they mediate immune destruction of FR\u03b1-expressing cells leading to loss of transport capacity. Ultimately, they signal broader autoimmunity.<br \/>\n[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]While both lead to cerebral folate deficiency, their distinct pathophysiologies\u2014<strong>functional occlusion vs. immune cytotoxicity<\/strong>\u2014dictate different diagnostic approaches, therapeutic strategies, and prognoses. Recognizing which autoantibody is present is essential for personalized treatment in neurodevelopmental and pregnancy-related folate disorders.<br \/>\n[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p>Both blocking and binding autoantibodies are detected using the <a href=\"https:\/\/www.fratnow.com\/\">FRAT<sup>\u00ae<\/sup> test<\/a>.<\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=&#8221;text-gray-23&#8243;][vc_column][vc_column_text single_style=&#8221;&#8221;]<strong>Disclosure:<\/strong><br \/>\nThe information provided in this blog is for <strong>general informational and educational purposes only<\/strong>. It must not be construed as medical advice. The content contained within is based on personal research, experiences, and opinions, and is <strong>not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition.<\/strong><\/p>\n<p><strong>FRAT<sup>\u00ae<\/sup> is not an FDA approved test. FRAT<sup>\u00ae<\/sup> is a lab developed test and performed in a CLIA certified lab. FRAT<sup>\u00ae<\/sup> requires the authorization of a physician.<\/strong>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Learn how blocking and binding folate receptor autoantibodies differ in mechanism, diagnosis, and treatment in cerebral folate deficiency.<\/p>\n","protected":false},"author":4,"featured_media":7594,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[70],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Blocking vs. Binding Folate Receptor Autoantibodies<\/title>\n<meta name=\"description\" content=\"Learn how blocking and binding folate receptor autoantibodies differ in mechanism, diagnosis, and treatment in cerebral folate deficiency.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Blocking vs. Binding Folate Receptor Autoantibodies\" \/>\n<meta property=\"og:description\" content=\"Learn how blocking and binding folate receptor autoantibodies differ in mechanism, diagnosis, and treatment in cerebral folate deficiency.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/\" \/>\n<meta property=\"og:site_name\" content=\"fratnow.com\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/autismfrat\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-06T13:00:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-06T13:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/06\/blocking-vs-binding-folate-receptor-autoantibodies-blog-listing-image.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"730\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Steve Tsetsekos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Blocking vs. Binding Folate Receptor Autoantibodies\" \/>\n<meta name=\"twitter:description\" content=\"Learn how blocking and binding folate receptor autoantibodies differ in mechanism, diagnosis, and treatment in cerebral folate deficiency.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/06\/blocking-vs-binding-folate-receptor-autoantibodies-blog-listing-image.webp\" \/>\n<meta name=\"twitter:creator\" content=\"@AutismFrat\" \/>\n<meta name=\"twitter:site\" content=\"@AutismFrat\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Tsetsekos\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Blocking vs. Binding Folate Receptor Autoantibodies","description":"Learn how blocking and binding folate receptor autoantibodies differ in mechanism, diagnosis, and treatment in cerebral folate deficiency.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/","og_locale":"en_US","og_type":"article","og_title":"Blocking vs. Binding Folate Receptor Autoantibodies","og_description":"Learn how blocking and binding folate receptor autoantibodies differ in mechanism, diagnosis, and treatment in cerebral folate deficiency.","og_url":"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/","og_site_name":"fratnow.com","article_publisher":"https:\/\/www.facebook.com\/autismfrat","article_published_time":"2026-06-06T13:00:33+00:00","article_modified_time":"2026-06-06T13:03:16+00:00","og_image":[{"width":730,"height":400,"url":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/06\/blocking-vs-binding-folate-receptor-autoantibodies-blog-listing-image.webp","type":"image\/webp"}],"author":"Steve Tsetsekos","twitter_card":"summary_large_image","twitter_title":"Blocking vs. Binding Folate Receptor Autoantibodies","twitter_description":"Learn how blocking and binding folate receptor autoantibodies differ in mechanism, diagnosis, and treatment in cerebral folate deficiency.","twitter_image":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/06\/blocking-vs-binding-folate-receptor-autoantibodies-blog-listing-image.webp","twitter_creator":"@AutismFrat","twitter_site":"@AutismFrat","twitter_misc":{"Written by":"Steve Tsetsekos","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["Article","BlogPosting"],"@id":"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/#article","isPartOf":{"@id":"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/"},"author":{"name":"Steve Tsetsekos","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/person\/d5e4020455f25cb3768f5eb9ad5e9f1c"},"headline":"Blocking vs. Binding Folate Receptor Autoantibodies","datePublished":"2026-06-06T13:00:33+00:00","dateModified":"2026-06-06T13:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/"},"wordCount":1184,"commentCount":0,"publisher":{"@id":"https:\/\/autism.fratnow.com\/blog\/#organization"},"articleSection":["Neurodiversity &amp; Wellbeing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/","url":"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/","name":"Blocking vs. Binding Folate Receptor Autoantibodies","isPartOf":{"@id":"https:\/\/autism.fratnow.com\/blog\/#website"},"datePublished":"2026-06-06T13:00:33+00:00","dateModified":"2026-06-06T13:03:16+00:00","description":"Learn how blocking and binding folate receptor autoantibodies differ in mechanism, diagnosis, and treatment in cerebral folate deficiency.","breadcrumb":{"@id":"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/autism.fratnow.com\/blog\/blocking-vs-binding-folate-receptor-autoantibodies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/autism.fratnow.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Blocking vs. Binding Folate Receptor Autoantibodies"}]},{"@type":"WebSite","@id":"https:\/\/autism.fratnow.com\/blog\/#website","url":"https:\/\/autism.fratnow.com\/blog\/","name":"fratnow.com","description":"","publisher":{"@id":"https:\/\/autism.fratnow.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/autism.fratnow.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/autism.fratnow.com\/blog\/#organization","name":"fratnow.com","url":"https:\/\/autism.fratnow.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/08\/logo.png","contentUrl":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/08\/logo.png","width":194,"height":66,"caption":"fratnow.com"},"image":{"@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/autismfrat","https:\/\/twitter.com\/AutismFrat","https:\/\/www.linkedin.com\/company\/88011685\/admin\/","https:\/\/www.instagram.com\/fratautism\/"]},{"@type":"Person","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/person\/d5e4020455f25cb3768f5eb9ad5e9f1c","name":"Steve Tsetsekos","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/09\/e6cec733-36d3-42ae-a0a7-986995164499_medium.jpg","contentUrl":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/09\/e6cec733-36d3-42ae-a0a7-986995164499_medium.jpg","caption":"Steve Tsetsekos"},"sameAs":["https:\/\/autism.fratnow.com\/blog\/"],"url":"https:\/\/autism.fratnow.com\/blog\/author\/steve-tsetsekos\/"}]}},"_links":{"self":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts\/7593"}],"collection":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/comments?post=7593"}],"version-history":[{"count":1,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts\/7593\/revisions"}],"predecessor-version":[{"id":7595,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts\/7593\/revisions\/7595"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/media\/7594"}],"wp:attachment":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/media?parent=7593"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/categories?post=7593"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/tags?post=7593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}